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Since William Wering (1) codiied the use of cardiac 
glycosides in his classic monograph on the pharmacology f 
the leaves of the common foxglove plant (Digitalis purgurrcl) 
in 1785, these agents have played aprominent role in the 
therapy of congestive h art failure. Even at the turn of the 
last century, however, controversy existed regarding their 
elkacy and appropriate indications, as reilected in the 
debate between the two coeditors of the O$mi Medicine, 
Sir James Maclcenzie and Henry Christian. On the basis of 
extensive clinical experience, Mackenzie advocated using 
digitalis only in those patients with heart failure who had 
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atrial 6b&lation, whems Christian (2) arped that “. . . 
digit&s. . . hasasbikingelfectonthosech~sinthe 
patient which a brought on by cardiac insuUiciency, end 
thiselkctappearsirrespectiveofwhetherornotthepulseis 
irregplar.” 
The views of Christian prevailed in the pmctice of car- 
diovascular therapeutics, at least in the United States, until 
reportsfromseveral unwatroUedtriak3inthelate197Osand 
early 1980s questimed the eUicacy of digoxin in most 
patients with heart tilure and particuhuly those with normal 
sinus rhythm. This examination ofthe safety and ekacy 
of diis glycosides par&led the introduction of newer 
and potentially ess toxic tmtmeMs forbothhemtmre 
and supraveatricular arfhythmias, inchldin& loop dhlmic 
drugs, vasodkm therapy, calcii channel blocking egents 
aad beta-adrenergic antagonists. Over the past decade, 
however, contmkd clinical trials have appemd, including 
several large pmspective randomized trials. that Benefit 
supporttheuseofdigo;ninforthetreatmentofsy~of 
heartfgluse,eitherGthd&eticdrugsorincombinab 
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severaistudiesofdigoxinappearedefter1%9,w~ 
statraudLuchi(3)questionedtheassersiopdChristianthst 
mostifnotalipxtiemswithconqestivehealtfaibuebeneih 
fnwr long-&m digit&s therapy. some smaii triais (4-s) 
examh&theeEectsofwithdrawaiofion&termdiqoxin 
therapyin,forexample,@atricpatientsinextendedc=e 
~skrwhomthed@osisof~tiveheartiWre 
and the indications forinstii dii therapy OrisiaallY 
weft poorly cluuacbrizcd. The di&dty in interpreting 
~~se~bya==tstudy6J)tbatattem~ . appmpmmessofdqpxmthempyma 
gerMcexte&dcareittstMonandto~obiec- 
tivelythee%tentofvcntricnIardysfirnctionwithtwo- 
. . 
dmcmoxd and Doppler echacardioegephy. Most of these 
patients (75%) receiviag digoxin had a n0rd (HO%) sys- 
toliCqjection~(8),~y5O%badnormal 
simurhytbmudinah0steverycase,the0rigidindica- 
tionsfordigoxhMerapycouidnotbedetcrmined(P).M 
pldhtSWithWCllpnservcdSptiCfunctiOOdsinus 
rhythmdas~tic 2montbsafterdigOxillwitb- 
drawal. Imllically,however,despi~readyaccesstolMdenl 
dia@lostictechniquesthatallowedano4jsctiveassessmeat 
Ofthe-dthe!Hlcce~withdrawalOfdigoxin, 
4o%Ofpatientswitbsinusrhythmandan~OnfrectiOO 
>so%wereexcludedfromthestlKly~tllepntient’s 
physician~t0allowdiscOntinuationoftlledlUg(9). 
EvenlessclinicdinfomMionisavailablefmmmany0f 
the earlier studies that mOnitored patients after withdrawal 
ofdi#oxin,andmOstofthesestudieswerenOtcolltroued 
tlhls.Alt~theini~reportbystarrandLuchi(3) 
. . 
~efkcyofdigoxinwasapiaceblWonMM 
double-blbldstudyoflleideriypatientswithsymptomsof 
hautfail~audsinusrhythm,theplvSenceofcongestive 
hCUtMUICWUllOtdOClUBlltCdill!JWdOftheStUdkS 
thatMowed.Evenwhenthedhqpux&ofconge&iveheart 
luihtrewasestablished,asinthedouble-biind,pkeblP 
controlled sipele aussover t ial by Dobbs et al. (10). data 
kltpatkntswithatriaifibriUationaudnonuaisinusrhythm 
wetewmbinedandtheiroutcomewasnotdi&entiated. 
The inconciusive evidence from the studies published in 
thedscadebef~198O~thetteedfoprandomized 
conuol clinicai t&is with adeqmly characterized patient 
8rOUPB.~l~,ArPddetal.(ll)reportedtheresultsofa 
~spedivetrielinasmallnumberdpatientswithmoderate 
heartfuilure,whosemeanqjectbm~was30~14%as 
determiaedbyqatedbloodpwiscinti2mpby.Duriugactive 
drug~,thestatusoftburpatkntsinNewYorhHeart 
~classIIIimprovedtociassII,butnopatient 
with class II status at the inbiation of the study showed 
improvement. DIM@ withdrawal ofactive drug, there was a 
signikaut inuzase in ieft ventricular end-d&ok pressure 
audadectwueincardiacindexinpatientswithciassIII 
heart faihue (11). Several subsequent small studies employ- 
iuq a prospective crossover design were published arly in 
the19808butyieldedconiWngresults.Usingclinicalend 
poi ts uch as the incidence of orthopnea and paroxysmai 
noctutnai dyspnea, s weii as objective functionai crkria 
such as exercise capacity and echoct&ographic determina- 
tiondleftveatricularfunction,Flegetal.(12)reportedtheir 
observations in 30 patients with class II and III heart failure 
in a double-biind, placebo-controlled crossover triai. Duriug 
3 months of foliow-up, although t ey discerned smail but 
statistMy significant worse&g of left ventricuiarfunction 
during digoxin withdrawal aud its reversal during reinstitu- 
tion of active drug therapy, there were no sign&ant diir- 
cnces in ciinid end points uch as maximai &eadmiil 
exercise duration, maximal exercise heart ute and fre- 
quency and severity of symptoms f congestive failure. In a 
simklydesignedtrialof22patientsreportedbyTaggsrtet 
ai. (13), there was no improvement in clitical end points 
duringtheactivedrugphase, althoughasigniiicaut reduction 
inheartrateatrestandasmailbutsignikantsborteningof 
systolic time intervals were detected. In contrast tothese 
twostudies,athirdtrialfnrm~earlyl~sbyLeeetal. 
(14), which also employed a double-blind, placebo- 
conttolied crossover design, documented the e2icacy of 
d qoxin 25 ambuiauuy patients with heart failure and sinus 
rhythm. Aithougb this trial excluded patients with class IV 
congestivehesrtfaihue,itisoftencitedasjWiQiugthe 
&ninistration ofdigoxin to patients with more advanced 
failure. The investigators used echocardiiphic indexes of
left v ntricular dysfunction a d chest roentgenographic 
signsafheartfailure,aswellasascoriags~~basedona 
physicMsassessmentoftheextentofpatientsignsand 
sy ptoms, which included rales on auscultation ofthe lungs, 
auaudibiethirdsoundgaliopandsignsofright-sidedcardii 
faiiure.Theydetermiuedthat14oftheir2spatientswere 
diixinrespomk.Ifpatkntswitheitheranormai&ction 
fmction on echocadie evaluation or consistently 
t&&ape& digoxin leveis (that is, CO.5 n#mi) through- 
~theactivedrugphaseofthetriaiareexcludedfromthe 
final analysis, then 14 of 16 patients were diqoxin respond- 
er&The reasonsfiuthismarkediypositiveoutcomecom- 
pared with the results of Fieg et al. (12) and Tagqsrt et ai. 
(13) remain unclear. Virtuaiiy aii patknts in the study by 
Taggatt e al. (13) had only miid (class I or II) congestive 
healtibibJre,whereastheentrycritekforthetrialbyFleg 
et ai. (12) do not permit identkkm of patients with 
unstuble or worsen@ symptoms of congeutive heart fuihue 
or other factors that would allow carelid subgroup analysis 
toidentifypatkntslihelytorespondtodigoxbLTheume- 
8tricteduseofothercardiacmedications(iucl~dhuctic 
dN#)illbothtbesetliai!SalsoUWIplicatestheWnlpkWnaf 
dataamongtriais.OneimporWltdis~c~is- 
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tic may be the mean daily dose of digoxia dministered, 
which was 0.435 mg/day in the trial by Lee et ai. (14) 
compared with 0.24 mg in that by Fleg et al. (12), although 
the stated target range for serum digoxin concentrations wa  
the Same in both triais. (No average diixin dose was 
reported in the study by Taggart et al. (13). 
The observation that patients with more severe l ft ven- 
tricular dysiunction appeared to have a more consistent 
response to digoxin wan supported bya study (15) in which 
patients with advanced congestive h art failure received 
short-term intravenous digoxin during invasive hemody- 
namic monitoring. Patients with decompensated congestive 
heart failure demonstrated marked improvement in cardiac 
output (+48%), left ventricular filling pressure (-36%) and 
ejection fraction (+8%) after diixin in zontra.3t to those 
patier& who were relatively weii compensated with diuretic 
drugs and vasodiWrs (15). 
These data suggested heexistence of a subset of patients 
who would respond todigitaiis giycosides, a concept sup- 
ported by a small but carefully controlled study in 20 patients 
with congestive h art tXhue reported by Guyatt et ai. (16). 
This wan also a piacebo-controiied crossover t ial that, 
among other measures of outcome, included a muiti&ctoriai 
heart failure score similar to that used by Lee et al. (14). 
Guyatt et ai. (16) aiso aimed for an average daiiy digoxin 
dose similar to that reported by Lee et ai. (14) (that is, 
0.4 mgky) by targeting a serum diixin concentration 
between 1.2 aud 2.1 ng/ml. Seven digoxin responders, de- 
fined as those patients whose symptoms worsened during the 
placebo phase of the trial, were identifted among the 20 study 
participants, whereas no patient had a worsening of symp 
toms during the active drug phase. Exercise tolerance, as
judged by a &uin walking exercise t st, was marginaily 
improved on active drug therapy. of the seven patients who 
were judged to have class III heart faihue at entry into the 
study, six were de&miued to be digoxin responders (16). 
Although none of the study patients demonstrated any 
evidence ofdigoxin toxicity, the dose of digoxin used in this 
study wan somewhat hi&er than that ypicaily prescribed in 
ciiuicaipracticetoday.TheroutiueuseofhigherdoSes 
would nece~sariiy in~ease the risk of toxicity in a hqe 
group of patients with heart failure. This point highhghts the 
need to identify those patients who would beneiit from 
digoxiuatMltherapeuticdosesbecause>SMofthe 
patients inthis study (16) had no evident cliuical response. 
Severalotherreportsofsmalltrialsappearediuthe 
mid-198Os, including a negative digoxiu withdrawal study by 
Aronow et al. (17) in geriatk patients with mild, well 
compensated congestive heart failure who had sinus rhythm. 
of the 10 patients studied, none required reinStitution f 
digoxinbecau~eofworseningsymptomsofhwrttbihrre. In 
oneoftheiirsttriaBtowmparedigoxindirectlywithau . aqgtotensibconvertiug enzyme iahii, Akandri et al. 
(18) reporkd adouble-blind, raudomM crussover trial of 
digoxin (average dose 0.25 u&lay) venws captopril (B mg 
a placebo phase. All patients received maintenance diuretic 
drg therapy as needed throughout each phase. In patients 
with mild to moderate h art failure, both exercise duration 
and tota! work performed during astandard exe&Se proto- 
col were sigaiiicantiy higher in patients aking either active 
drug compared with piacebo. Blood pressure decreased 
during captopril therapy, but no patient became symptom- 
atic. 
Recent Multicenter This 
lwmma@d study. six htrge Jnulticenter raJu&Ju- 
ixed chical trials have appead shx 1988. The digoxiu 
xamoterol study (19) examined the e&ctS of xamoterol, a 
beta,-selective mixed agonist with Some beta-antagonist 
activity, compared with those of either piacebo or digoxin. 
Although 300 of 433 patients completed the double-blind 
phase ofthe trial with exercise t sts at entry and at 3 months, 
the patient group was incompletely characterized. There was 
no documentation of systolic function, and most patients 
(87%) were deemed tohave only mild (class I or 11) symp 
tams of wngestive heart failure. The dose of digoxin em- 
ployed was relatively low (0.125 mg/day), leading toa mean 
steady state digoxiu level of only 0.87 ug/ml. only xamoterol 
improved xercise duration at3 months, an e&ct that wuld 
inpartbeduetothebenekiale&ctsofpartialbeta- 
adrenergic blockade in patients with some underlying isch- 
emit disease (19). Both digoxin- and xamoterol--ted 
groups, however, demonstrated iesscning ofsymptoms wm- 
pared with findings in the placebo group. Xammerol has 
subsequently been shown (20.21) toincrease the mortality 
rate in patients with advanced heart failure. These and 
another recent report (22) indicate that he cause of death 
may not have been the increased frequency or severity of 
ventricuiar rhythmias, but rather an acceletatiou f the 
undeliyin# heart faihue. 
ThecnptoppBdigwhtrlaL Thistrial(23)wmparedcap 
topril,digo~audplaceboin3OOpatients,85%ofwhom 
werejudgedtohavemiid(ciassIorII)wngeStiveheart 
fldiure. During the initial evaluation beforv entry into the 
triai, patients whose heart failure worsened during with- 
drawai of maintenance digoxin but whiie receiviug dhrretic 
drug8 were disquahlied, thuS excMiug anumber of sul$ectS 
whowouidbydefmitiouhavebeeudi@xiu~. 
Patients were raudomixed to receive ither captopril, 
diixin or piacebo (that is, no crossover phaSe) while 
wntinuingoumainteuancetherapywithdiureticdrugS~GniY 
captopril &n$cantly increased xercise duratiou (by 1496, 
p<O.O5)wmparedwithan &reaseof6%forpiaceboand 
dlO%foAigoxiu,whereasoniydigoxininduceda~~t 
~cant~reaseioleftventric&r&ctionfractkm.How- 
~~,digoxhrandcaptoprBwereequaliy~e~~uc- 
ing&no&idityaSSociatedwithwonseningsYmptomsof 
~failureaSjlldgedbyinCRWXddilKetiCrequire~nts, 
hospital stays and number ofemeqeucy room visitS (u)- 
1lOA KEUYAND8MlTH 
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~venmsdlg8xi8trial. D8viesetal.@0recentlY 
reported~eresultsofatrislinwhichl4!Ipatkntswlthmild 
tonn&ute(classIIorIII)heartfailureuu+vht8diuntic 
~~randonnizedtoreceiveeither~(average 
dose 19 rug/day) ordigoxin (average dose 0.284 u$daY)- 
&t&antlytkwerpatientsshowedclinkal~ 
~enelaQpilthanwi&digoxininthisstudy.Althoughat14 
~tbllllkOf~ti~tSW~conditionimprovedweS 
~hbothgmlps,the~drapoutofpatimts 
. ~todigoxinkapymahesitimpossibletodraw 
any fxmwcms at thi!J time. unlike the aptquil*ti 
trial just descrii, in this study, patients already tuceiving 
digoxiiwhomettheentryfzit&wereqiven8~boin 
pleaddigoxiafor2weelcsandwerecarefuhymonitored 
f~cli&aldeu&u&l,with~ustmentofdiureticdrug 
dosebekrerandomizetionifnecessary.Onlytwopatients 
were&quali6edfremrandomizationbeforeinitiationofthe 
activedrugphase.lUostpatkntswhohadtobepr-turely 
withdrawnfromthedigoxinamldthetrialbecauseofan 
adverseclinkaleventweluwithdrawnwithintheilrstsev- 
dWCCkS,WhweastllCclinical~sponsetObOthenalapril 
anddig@nappearedtobesimilarbetween4andI4weeks 
andpruktedthat~tdecressesinsymptomsshould 
occurwhenthedruqswereusedin-. 
~~~D4l=ln=WG~- 
SWGm~agroupO-yreported~prelim- 
inaryresultsofa~etrialcomparlngcaptopril, 
digoxhtandphtceboinpatlentswithsymptomsconsistent 
WitllddtOmoderate(ChSSIIOrIII)COUgdVCheart 
failure. After an initial phase with patients receiving uo 
drugs, the GADS Gtoup documented sign&ant improve+ 
mentin&ctionikactionandgeneralwellbein9inpatients 
siven~@=uWY)~pared~~(25nrS 
twiceaday)orphuzebo.Therewasnodikenceinexercise 
tolerance m the three pups. The average left ventric- 
ularejectkmfktionwasrehttivelywellureservedatabout 
5O%b&rera&mMoninallthteeqtuupsandthedaily 
Wmparmq ananqtotenshkconvertinq nzyme 
inhiiwithdigoxin(25). 
frrs~sYmptomatkbenefttwhenaddedtoastan- 
darddiureticdnqtreqimeninpatientswithovertheart 
faihue. Given the convincii evidence ofsun+fal bcneik of 
anqiotensin-converthtg nzyme it&iii in patients with 
symptomatic systolic dysfunction, however, the relevant 
q~stioairlourviewnowistheinctumentalbeneiltof 
dWnwhenaddedtoare@nenthatinchulesdhu&~ 
and vaslMlilatars, the latter most OftAn being an angiutensin- 
-vuting enzyme inhibim (see later). 
me mwKJ~ trial This tlid (26) studid w) 
tints with Ielatively severe (class III or IV) heartfaihu& 
The p&lent8 were raulomixed to receive placebo, digoxin, 
mWoneoracombi~ofbothdrugsinadditkmto 
baselk dimetic drug therapy. Milrinone isa phosphodies- 
teraseinhKtorthatactsbothasavasodilatorandasa 
positive inotiopic wnt. There were two main conclusions 
6omthisstudy.1)Di@nimproved~ectionfmctionand 
exercisetoleranceatdmarlsedly~thefrUIuencyof 
clinical decompensation compared with that in either the 
placebo ormibhume groups (the incidence ofdecompensa- 
tion in the digoxin plus milrinone group was intennediste). 
2) Ventricular ectopic activity was siqnikantly more fre 
quentithegrouprandomkltoreceivemilrinonethanin 
eithertht?digoxinortheplacebogroup(26).Theseilndings 
were xtended bya multicenter rial of mihinone insevere 
heart failme (the Prospective Rat&m&d Mihinone Sur- 
vival Evaluation [PROMISE] trial [nl), in which patients 
with class III or IV heart failure were r&on&xl to receive 
either &inone or placebo t  supplement optimal medical 
w ofdigoxht, Wodihnors aud diuretic dru@. luilri- 
non marhedlykeasedthemortabtyratecomparudwith 
placebo, particularly in patients with the most severe heart 
faihue, whose mortality rate was 53% higher while receiving 
the oral phosphodiesterase inhibitor. The results of the 
PROMISE trial (27.28) comb&d with data &om smaller 
hials of other phosphodiesterase inhibitors, including enox- 
intone (29) and kxodan (3(l), and the results of the diixin- 
xamoterol study (19) already noted, serve to maintain the 
status qu+aamely, that digoxin is the only positive ino- 
tropic agent available for long-term oral administration in 
pat ents with heart failure that lessens symptoms without 
any ~8nixed hauease (or decrease) in mortahty (see 
subsequent comments regard@ the DIG trial). 
Gtkrtrlak Several small prospective trials have xam- 
in !dtheelkctofaddhtgdi@ntotheregimenofpatients 
alreadyr&vingvasodilato~anddiureticdrugs.Arecent 
study by Gheorghkk et al. (31) of patients with sinus 
rhythmwhohadmoderaktosevereheartfailtucdocu- 
mUttUlthat,whenaddedto~therapy,diixin 
w favorable eifects on hemodynamic variables and 
exercise tolerance that substantially exceeded the responses 
obserwd when either drug was given alone. These improve 
mentsinfunctionalcapacitywere~paniedbyaptompt 
decline inplasma notepinephrine a daldosteume levels in 
patients receiving digoxin and captopril but not capU@l 
alone. Studies by several other groups (3Z35) have also 
documentultbattheaddit&ofdigoxininp&ntsreceiving 
an established teghuen ofdiuretic drugs and vasodWors 
improves cardiac output, reduces ventricular Ming pres- 
sures, kreases exercise capacity and minimizes the inci- 
dence of symptomatic hypotension ften seen in patients 
with congestive h art tkilure treated with vasodWors and 
diureticdrugs.Fughetal1.(35)demonstratedthatthecondG 
tionofsi@kaWlymorepatientswithmiicongestiveheart 
faihuedet&m&dwhendigoxinwaswithdrawn6oma 
stablemedicaltgimenincludingdiuteticdrugsandvasodi- 
lators (11 PS%l of 44 patients) than when digoxin was 
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ctmtinued (5 [I l%] of 44 patients). Although t eirs was a 
randomized, ouble-blind, placebo-controlled crossover 
trial, most patients in the study did not have objectively 
determined severe systolic dysfunction. Thus, it is dillkult 
to compare these data with data from other ecent trials 
(16,23-25,31,35) where serial objective measures of left 
ventriudar iimction in addition to patient aud physician 
assessment of symptoms were monitored. 
InamaU,prospective, raudomixedcrossovertnkl(36)to 
assess the bet&s of the short-term administration of 
digoxin on maximal exercise capacity aud left ventricular 
function i  patients with class II or III heart failure already 
optimally treated with vasodilators and diuretic drugs, 
digoxin (average s nnn level 1.4 n&l) improved aerobic 
performauce only in patients with a low baseline exercise 
capacity (that is, maximal oxygen uptake Cl5 ml/kg per 
mitt). This e&t of digoxin was statistically siqnikut 
despitethesmaumunberofsubje&audthelmcon~ 
use of other drugs (fbr example, only 50% of the patients 
were also talc@ vasodilators) (36). 
In a prospective trial (37) examin@ factors that would 
determine the clinical outcome iu a cohort of69 patients with 
a primary diaguosis of left ventricular f ilure studied longi- 
tudinany, previous ueatmem with digoxin or anqiotensin- 
converting enxyme inh&itors, or both, tended to predict s 
shorter hospital stay compared with that for patients not 
receiving either drug at the time of hospital dmission, 
although t e extent of left ventricular dysfunction as well as 
othervariabkssuchashypokalemiaandadvancedagewere 
much sttonger p edictors of a prolonged hospital stay and 
outcome (37). 
TrlaB of dlpaxlu withdrawal. Finally, two trials reported 
recently employed a ran&mixed digoxin withdrawal design 
reminiscent, albeit n a more rigorous format, of early trials 
thatque&nedthee&acyofdigoxininpatientswith 
congestive h art Slure in sinus rhythm. Both the Prosp 
tive Bandomixed Study of Ventricular Failure and ERcacy 
OfDigoxiu (PROVED) (38) aud the &&mixed Assessment 
ofDiixin on Inhibitors of Angiotensin Converting Enxyme 
(RADIANCE) (39) studies are multicenter placebo- 
controlled trials examin& the effects of withdrawal of
digoxin tberapy iu patients with stable congestive h art 
failure symptoms (class II, El). No patient inthe PBOVED 
trial was treated concurrently with an angiotensin- 
converting enxyme inhibitor, whereas all patients in the 
BADIANCEtrialreceivedawnstantdoseofanau&ten- 
sin-converting e zyme inhibitor as well as diuretic druqs as 
needed.Inbothtrials,criteriafwemoBmentiucludeda1eB 
. 
vemmlar qjectbn fkaction s35% aud the target serum 
digoxin concentration during the baseline run-in phase was 
0.7to2ng/ml.Thewithdrawalphasewas12weeksinboth 
studies. Ia the PBOVED study (38). 18 (3%) of 46 patients 
during withdtawal to placebo noted asiguillcant worsening 
of heart failure symptoms wmpared with 8 (19%) of 42 
receiving active drug. In the RADIANCE study 09), the 
condition of2596 detetiorated during placebo with concur- 
rent anqiotensin~nverting enxyme inhiW&d&tic anrg 
therapycomparedwithdeteriorationin0nly5960fthose 
rcoeiving digoxin, au angiotensin-convertiqg enzyme ati- 
tar and diuretic drugs. Both studies upport the use of 
digOXin in the treatment of symptomatic congestive h art 
failure due to systolic veutricuk dysfunction. ~ltbough a 
ri@Kouscomparisonoftlleresultsofthesetwo~ 
trials is not possible, we suspect that he 5% kidence of 
clinical deterioration during treatmeut with diuretic drugs 
plusauangiotensiu-convertingenxymeeazymeplusdiqoxiu 
representsarealandclinicallyimportantimprovemento~~ 
the 19% inciin~ of worseninq in the PRGVEB t&l pa. 
tientsreceivingdiureticdrugsanddigoxinwitboutauangio- 
tensin-converting euxyme inhii. Both trials tudied pa- 
tients with only mild to moderate symptoms of wngestive 
heartfailure.Iktientswithmoreseverecouge&eheart 
tkilure (class IV), a group for whom digoxin had already 
been shown (15%) to lessen symptomx were xcluded by 
design from enrollment i  either trial. 
TlieBlgpaBsIn~Gronptlial. unlikevasodBa- 
tors aud particularly the angiotensin~vertinq enxyme 
inhibitors,cardiacglycosidesbavenotbeen~to 
improve survival in patients with wngestive heart lbilure, 
possiblybecauseeachofthetrialsjustsummakedwastoo 
smalltodetectanybutverylargepositiveoruegativee&cts 
on mortality rate. This question is now beinq addressed by 
the prospective, raudomM placebo-controlled Di&lis 
Invest@tors Group (BIG) trial, sponsored bythe National 
Heart,Lung,audBloodktituteoftheNationalInstitutes 
afHeaith.Todetecta1096tolS96changein~ynrte, 
it is anticipated that about 8,lMO patients will riced to be 
enrolled. Enrollment is nearing completion as of July 1993 
and results are auticipated in 1995. Aside from the primary 
aimofdeten&@theektofdiqoxinontheinchWceof 
dWh,secondarydpOiOtS~~hSymp 
tomsasdetectedbyseveralclinkalendpoints,aswellasa 
quality ofl& score. Before nrollment, patients must have a
leftventricuk&ctioniktion<45%audmustremainin 
cliuiMystableconditionforh2weeksontreetmePtwithan 
. . 
angtoteosurcanvertiasenzymeinhibitorwithorwithout 
diUEtiCdnrgsaSlICCdCd~~tbeySred~to 
receiveeitherdigoxinorplace~.Atleast5O%ofthe 
~s~mt&&akmwillnothavereceived 
mahttenancediixintherapybefoteenrollmentinthetrial, 
thusdimininhhtgattypotentialbiasduetoaprolonged 
“digoxin withdrawal- effect. 
. . 
bphd10~ Thus, a number of clinical trials over the 
past2Oyearshavevalidatedtheclinicalimpr=knofHemy 
Christian~)thatdigitahsdecreasessymptomsduetoa 
failingh~irrespectiveofwhetherthehettrtt’hythmis 
regtlkAcatUioWanalysisofthesedatawouMsupport~ 
~~t&utofdigoxintoaregimenoftreatmentwitha~c 
drug and a vawdikor (usually an attgioteusin-convertinq 
enyme inhibitor) inmost patknts with moderate to severe 
heart failure symptoms due to systolic ventriadar dyafunc- 
tion.BigoxinmaylessensymptomsinaLimited~~ 
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